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At the European Society of Cardiology (ESC) congress of this year 2018, held in Munich from
August 25th to 29th, 4594 abstracts were presented. Of those, 423 (10.8%) belonged to an
imaging category. Experts in echocardiography (VD), cardiovascular magnetic resonance
(CMR) (CBD), nuclear imaging (OG), and cardiac computed tomography (CT) (PMH) have
selected the abstracts in their areas of expertise that were of most interest to them and are
summarized in this bird’s eye view from this ESC meeting. These abstracts were integrated by
one of the Editors of the Journal (JB). (J Nucl Cardiol 2019;26:76–85.)
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Abbreviations
CAD Coronary artery disease
CMR Cardiac magnetic resonance
CT Computed tomography
FDG 18F-Fluorodeoxyglucose
GLS Global longitudinal strain
LGE Late gadolinium enhancement
LV Left ventricular
LVEF Left ventricular ejection fraction
PET Positron emission tomography
TEE Transesophageal echocardiography
ECHOCARDIOGRAPHY
Coronary microvascular dysfunction as mechanism
underlying the pathophysiology of heart failure with
preserved left ventricular ejection fraction (LVEF) was
evaluated in the prospective, multicenter PROMIS-
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HFpEF (PRevalence Of Microvascular dySfunction in
Heart Failure with Preserved Ejection Fraction) trial.1
Coronary flow reserve (CFR) was measured with
adenosine stress transthoracic echocardiography in 202
patients with heart failure and preserved LVEF. In
addition, left and right ventricular systolic functions
were assessed with conventional and speckle tracking
echocardiography and systemic endothelial function was
assessed by peripheral arterial tonometry (Figure 1).
Three quarters of the patients had coronary microvas-
cular dysfunction (defined by a CFR\ 2.5). Patients
with coronary microvascular dysfunction were more
frequently active smokers (70% vs 43%), had more
frequently atrial fibrillation (58% vs 35%), and pre-
sented significantly higher levels of NT-proBNP (1050
[396-1930] vs 597 [190-1410] pg/mL; P = 0.004) and
troponin T (14.0 [10.0-25.6] vs 10.0 [10.0-16.4] ng/mL;
P = 0.002) compared to patients with preserved
microvascular coronary function. Despite similar LVEF,
patients with coronary microvascular dysfunction
showed more impaired left ventricular (LV) systolic
function as assessed with tissue Doppler velocity (s0)
(6.3 ± 1.6 vs 7.3 ± 2.1 cm/s; P\ 0.001) and speckle-
tracking global longitudinal strain (GLS) (15.7 ± 3.5 vs
17.0 ± 3.5%; P = 0.023) compared with their counter-
parts. In addition, patients with coronary microvascular
dysfunction showed more impaired right ventricular
longitudinal strain (21.6 ± 5.2 vs 23.3 ± 5.1%;
P = 0.005) and lower reactive hyperemia index as a
measure of systemic endothelial function. These results
suggest that coronary microvascular dysfunction may be
an important pathophysiological mechanism of heart
failure with preserved LVEF and may set the basis to
develop effective therapies that target this mechanism.
Cardiac amyloidosis is characterized by diffuse LV
hypertrophy and on speckle tracking analysis, the LV
GLS is characterized by a typical apical sparing (with
more preserved values of longitudinal strain in the apex,
while mid and basal segments show severe impaired
strain values). This LV GLS pattern is associated with
poor outcomes.2 Diffuse LV hypertrophy can be
observed in other diseases (hypertension, sarcomeric
mutations…) and the prevalence and prognostic impli-
cations of relative apical sparing LV longitudinal strain
in those other etiologies of LV hypertrophy are
unknown. In 399 patients with diffuse LV hypertrophy
and no significant coronary artery disease (CAD), Saito
et al3 showed that relative apical sparing of LV
longitudinal strain was present in 10% of patients.
During a median follow-up of 4.8 years, 50 patients
presented with major adverse cardiovascular events
(MACE) (cardiac death, heart failure or acute myocar-
dial infarction). The pattern of relative apical sparing of
LV longitudinal strain was more frequently observed
among patients presenting with an event. A relative
apical sparing LV longitudinal strain index (ratio
Figure 1. PROMIS-HFpEF study algorithm. In patients diagnosed with heart failure with
preserved left ventricular ejection fraction (HFpEF) and nonsignificant coronary artery disease,
coronary microvascular dysfunction was assessed based on quantification of coronary flow reserve
with adenosine stress transthoracic Doppler echocardiography. In addition, conventional and
speckle-tracking echocardiography was used to evaluate left and right ventricular systolic function.
Peripheral arterial tonometry was used to measure systemic endothelial dysfunction. Reproduced
with permission from Shah et al1.
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between the value of apical longitudinal strain and the
average longitudinal strain of basal and mid ventricular
segments)[ 0.6 had incremental prognostic value over
clinical and conventional echocardiographic parameters
to predict the outcome. These results extend the
evidence on the prognostic relevance of relative apical
sparing LV longitudinal strain to other causes of LV
hypertrophy.
A novel method that integrates blood pressure
measurements and LV GLS provides noninvasive LV
pressure-strain loops and permits calculation of global
and segmental myocardial work in various cardiac
diseases. Edwards et al4 estimated global and regional
myocardial work and wasted work in 10 controls, ten
patients with nonischemic cardiomyopathy and 14
patients with ischemic cardiomyopathy. Patients with
ischemic and nonischemic cardiomyopathies had signif-
icantly lower values of myocardial work compared with
controls. In addition, patients with nonischemic car-
diomyopathy showed significantly wasted work in the
septal wall compared with the lateral wall, suggesting
enhanced systolic LV lengthening with segmental
shortening during isovolumic relaxation, which can be
a target for cardiac resynchronization therapy. In con-
trast, ischemic patients did not show regional differences
in wasted work. This technology was also applied to
differentiate physiological from pathological causes of
LV hypertrophy in 20 controls, 24 professional athletes
and ten patients with nonischemic cardiomyopathy.5
Patients with nonischemic cardiomyopathy showed the
largest LV mass (317 ± 89 g) followed by the profes-
sional athletes (203 ± 57 g) and controls. However, in
terms of global myocardial work, nonischemic car-
diomyopathy patients showed the most impaired values
(723 ± 431 mmHg%) whereas the professional athletes
showed the highest values (1931 ± 485 mmHg%).
Therefore, the etiology of LV hypertrophy is an impor-
tant determinant of the global LV myocardial work.
Three-dimensional (3D) transesophageal echocar-
diography (TEE) is key in the evaluation of patients
referred for transcatheter aortic valve replacement,
particularly when the anatomy of the aortic valve is
bicuspid. In 104 patients with bicuspid aortic valve
stenosis, who were evaluated for transcatheter aortic
valve replacement but who were eventually treated
with surgical aortic valve replacement, Dr Wang6
evaluated the agreement between 2-dimensional (2D)
transthoracic echocardiography, 3D TEE, and com-
puted tomography (CT) to size the aortic annulus. The
reference standard was intraoperative sizing of the
aortic annulus. Measurements based on CT and 3D
TEE had the best agreement with intraoperative sizing
of the aortic annulus. However, the agreement between
3D TEE and intraoperative sizing was negatively
influenced by the presence of heavy calcifications of
the aortic valve.
Finally, the use of machine learning in echocardio-
graphy provides important insights. From the national
echocardiographic database of Australia (NEDA), a
vendor-agnostic cloud-based database containing
echocardiographic data from ten Australian laboratories,
Murphy et al7 evaluated the prognostic value of left
atrial (LA) volume index and LA anteroposterior diam-
eter. Data from 352,844 individuals with a mean follow-
up of 5.4 years/person were analyzed. A total of 63,142
deaths were recorded. Left atrial volume index (LAVI)
showed the strongest association with all-cause mortal-
ity. Individuals with a LAVI[ 42 mL/m2 (upper
quintile) had the highest age- and sex-adjusted risk
profile (hazard ratio [HR] 1.9 compared with patients
within the lowest quintile [LA volume index\ 22 mL/
m2]). The analysis based on deciles of LA volume index
showed that the increase in mortality risk began with the
LA volume index decile of 29-31 mL/m2 (which is close
to the cut-off value proposed by current recommenda-
tions to define pathologic dilation of the LA).8
NUCLEAR IMAGING
Cartlidge et al9 used 18F-fluoride positron emission
tomography (PET) to predict valvular degeneration of
bioprosthetic aortic valves. The hypothesis was based on
ex vivo experiments in 15 explanted degenerated bio-
prosthetic valves, which all showed intense 18F-fluoride
uptake coregistered to areas of calcification, fibrosis,
thrombosis, and disruption of the collagen structure on
micro-CT and on histopathology. In the in vivo study,
the investigators performed 18F-fluoride PET in 6
patients with aortic bioprosthetic valve dysfunction
(cohort 1) and in 71 patients without any known
prosthesis dysfunction (cohort 2). Patients were fol-
lowed up 2 years after PET/CT with echocardiography
and clinical assessment. In cohort 1, all patients exhib-
ited increased 18F-fluoride uptake on PET and leaflet
abnormalities on CT. Interestingly, in cohort 2, 27
(38%) patients had increased 18F-fluoride uptake with a
mean target-to-background (TBR) ratio of 1.55. Patients
with increased 18F-fluoride uptake demonstrated a
[ 10-fold increase in mean gradient over 12 months
compared to those without increased uptake (Figure 2).
On multivariable analysis, baseline 18F-fluoride uptake
was the only independent predictor of deterioration in
bioprosthetic function, and all patients with TBR values
C 2.5 had evidence of overt bioprosthetic failure within
1 year of imaging. The findings of this study suggest
that 18F-fluoride PET may be a powerful tool to detect
early bioprosthetic valve degeneration and guide subse-
quent patient management.
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Machine learning principles (e.g. deep artificial
neural networks = deep learning) are raising increasing
attention as innovative approaches to explore and learn
complex patterns within imaging data and improve
human interpretation of large data clusters. Juarez-
Orozco et al10 used a pretrained very deep convolutional
neural network modified through transfer learning for
the identification of patients who experience MACE
based on direct image processing of PET myocardial
perfusion polar maps. For this purpose, polar maps of
myocardial perfusion reserve from 1199 patients (625
female, mean age 68 years) undergoing 13N-ammonia
PET were analyzed. Deep learning was built through
transfer learning by obtaining the architecture of the
open source pretrained ResNet50 convolutional neural
network and replacing the last layer and associated
weights with a new layer specialized for the classifica-
tion of patients who experienced or not MACE using a
9:1 training to testing ratio and 5-fold cross validation.
Deep learning demonstrated an overall cross-validated
validation accuracy of 77% with a corresponding pre-
cision and recall of 90% and 72%, respectively, and a
specificity of 87% for identifying patients who experi-
enced a MACE on follow-up. The positive likelihood
ratio was 5.51, while the negative likelihood ratio was
0.32. The authors conclude that deep learning may offer
Figure 2. 18F-fluoride positron emission tomography and computed tomography predicting
deterioration in bioprosthetic valve function. Cases 1-4 depict the role of 18F-fluoride positron
emission tomography (PET) and computed tomography (CT) in predicting new bioprosthetic valve
dysfunction. None of the patients had known bioprosthetic degeneration at enrolment. Contrast-
enhanced CT images in the short axis of the valve (top row) show no clear structural CT changes in
case 1, non-calcific leaflet thickening in case 2 and circumferential pannus in cases 3 and 4. Hybrid
18F-fluoride PET-CT images (middle row) show high intensity 18F-fluoride uptake in each valve.
Doppler echocardiography (bottom row) shows the development of new valve dysfunction during
follow-up with progression to hemodynamically severe stenosis in cases 1 and 2, and new
prosthetic regurgitation in cases 3 and 4. Image courtesy of T. Cartridge.
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additional clinical value in the identification of patients
that will present MACE on follow-up.
Hybrid 18F-fluorodeoxyglucose (FDG) PET and
magnetic resonance imaging (MRI) permit differentia-
tion between myocardial scar from fibrosis associated
with inflammation. Spinelli et al11 explored the value of
FDG PET/MRI to detect early signs of myocardial
inflammation in patients with Anderson-Fabry disease.
Cardiac FDG PET/MRI and transthoracic strain
echocardiography were performed in 24 heterozygous
females carrying a-galactosidase A mutation and with-
out LV hypertrophy. Thirteen patients showed focal
FDG uptake (defined by a coefficient of variation in
segmental FDG uptake [ 0.17), including 2 patients
with late gadolinium enhancement on MRI. Patients
with a coefficient of variation [ 0.17 had worse LV
GLS compared to those with coefficient of variation
B 0.17 (- 18.5 ± 2.7% vs - 22.2 ± 1.8%, P = 0.024).
The authors conclude that focal FDG uptake is an early
sign of disease-related myocardial damage in patients
with Anderson-Fabry disease and is associated with
impaired LV longitudinal function. Moreover, their
findings support the notion that inflammation plays an
important role in glycosphingolipids storage disorders.
Keller et al12 report feasibility and safety profiles of
pharmacological stress testing with the selective A2A
receptor agonist regadenoson in 5151 consecutive
patients undergoing 99m-TcTetrofosmin myocardial
perfusion scintigraphy. The most frequent side effects
were shortness of breath (66.2%), headache (21.3%),
feeling of warmth (20.7%), feeling of pressure in the
chest (18.1%) and in the ‘‘stomach’’ (17.4%). A new
first degree atrioventricular block was observed in 0.1%.
In four patients (0.08%), a severe symptomatic brady-
cardia or even life-threatening asystole occurred which
could be immediately interrupted by administration of
aminophyllin and atropine. These side effects were more
often observed in patients with preexistent first degree
atrioventricular block. This prospective registry demon-
strates that regadenoson for pharmacological stress tests
is generally well tolerated with frequent but harmless
and transient side effects. Although very rare, life-
threatening asystole or severe bradycardia (0.08%) may
occur but can be rapidly treated with aminophyllin and
atropine.
CARDIOVASCULAR MAGNETIC RESONANCE
IMAGING
Watchful waiting in asymptomatic patients with
severe aortic stenosis and preserved LVEF is currently
recommended. However, the pressure overload imposed
to the LV by the stenotic valve can lead to irreversible
myocardial fibrosis which has shown to portend poor
prognosis even after aortic valve intervention. Singh
et al13 investigated whether adverse LV remodeling
progresses in the short term in 44 asymptomatic patients
with moderate-to-severe aortic stenosis (83.4% male,
indexed aortic valve area 0.54 ± 0.15 cm2/m2) included
in the PRIMID-AS (PRognostic Importance of
MIcrovascular Dysfunction in Aortic Stenosis) study.
Cardiovascular magnetic resonance (CMR) imaging was
performed at baseline and 12-month follow-up. The
authors observed a significant increase in indexed LV
end-diastolic volume (from 90.7 ± 22.0 to 94.5 ± 23.1,
P = 0.007) and indexed LA volume (from 52.9 ± 11.3
58.6 ± 13.6, P\ 0.001), reduction in LVEF (from
57.9 ± 4.6% to 55.6 ± 4.1%, P = 0.001) and impair-
ment in LV diastolic function (longitudinal diastolic
strain rate from 1.06 ± 0.24 s-1 0.99±0.24 s-1,
P = 0.026) despite no change in the indexed aortic
valve area. In addition, there was a significant reduction
in rest and stress myocardial blood flows and increases
in myocardial fibrosis both on native T1 mapping and
late gadolinium enhancement (LGE) imaging (Fig-
ure 3). These findings demonstrate unequivocal
progression of adverse cardiac remodeling in asymp-
tomatic moderate-severe aortic stenosis in 12 months,
emphasizing the need of improved patient risk-stratifi-
cation tools and potential need for earlier intervention.
Boldrini et al14 evaluated the accuracy of noncon-
trast CMR for clinical diagnosis of cardiac amyloidosis
in a large multicenter prospective study of 868 patients
with suspected systemic amyloidosis. In addition to
comprehensive clinical investigations, the imaging pro-
tocol included native (noncontrast) T1 mapping and
LGE imaging. The final diagnosis was light-chain
cardiac amyloidosis in 222, transthyretin cardiac amy-
loidosis in 214, and no cardiac amyloidosis in 427
patients. Native T1 was higher in patients with light-
chain or transthyretin cardiac amyloidosis compared
with patients without cardiac amyloidosis. The diagnos-
tic accuracy of native T1 to identify patients with
cardiac amyloidosis was excellent (area under the curve
0.93). A native T1\ 1036 ms was the most sensitive
value (99% sensitivity) to exclude cardiac amyloidosis
while a native T1[ 1164ms was the most specific (99%
specificity) to diagnose cardiac amyloidosis. Based on
these results, the authors proposed a diagnostic algo-
rithm with native T1 mapping to all patients with
suspected cardiac amyloidosis, whereas contrast admin-
istration and LGE imaging would be reserved for
patients with native T1 mapping between 1036 and
1164ms.
Feature-tracking CMR is a novel technique that
permits assessment of myocardial deformation on cine
CMR images. Using this methodology, Podlesnikar
et al15 evaluated the effects of early metoprolol on the
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LV systolic function in 214 patients with anterior ST-
segment myocardial infarction treated with primary
percutaneous coronary intervention. The patients were
included in the METOCARD-CNIC (Effect of Meto-
prolol in Cardioprotection During an Acute Myocardial
Infarction) trial and randomized to early intravenous
metoprolol vs standard care. CMR was performed 5-7
days after reperfusion, and LV global circumferential
strain (GCS) and GLS were measured using feature
tracking. During a median follow-up of 2 years, 22
MACE (composite of death, heart failure readmissions,
reinfarction, and malignant ventricular arrhythmias)
occurred. Patients with LV GCS[- 13.2% or with
LV GLS[- 11.5% (more impaired LV systolic func-
tion) who did not receive early intravenous metoprolol
showed the highest cumulative event rates compared
with the patients who received metoprolol or had more
preserved LV systolic function. These results underscore
Figure 3. Short-term adverse cardiac remodeling in asymptomatic moderate and severe aortic
stenosis by cardiovascular magnetic resonance. A representative patient undergoing cardiovascular
magnetic resonance at baseline at 12-month follow-up. There is a progressive increase in left
ventricular end-diastolic volume (LVEDV) and left ventricular mass index (LVMI), reduction in
left ventricular ejection fraction (LVEF) and increases in myocardial fibrosis by both native T1
mapping and late gadolinium enhancement (LGE) in the interval of 12 months, whereas the indexed
aortic valve area remained unchanged. These changes suggest adverse cardiac remodeling despite
no further reduction in indexed aortic valve area. Reproduced with permission from Singh et al13.
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the role of feature-tracking CMR for detailed risk
stratification of patients with ST-segment elevation
myocardial infarction.
Phase-contrast cine MRI of the coronary sinus is a
noninvasive method to quantify CFR which has been
associated with prognosis in patients with suspected
CAD. In 163 patients with diabetes mellitus, Kato et al16
assessed CFR during adenosine triphosphate infusion
and at rest using phase-contrast cine MRI. CFR was
calculated from myocardial blood flows at stress and
rest. During a mean follow-up period of 3.7 years, 20
MACEs were identified, and patients with CFR\ 2.0
had worse prognosis than those with preserved CRF[
2.0. On multivariable Cox regression analysis, CFR\
2.0 was independently associated with MACE (HR
11.29, P\ 0.001). The study demonstrated that a
noninvasive CFR assessment by phase-contrast cine
MRI could represent a novel risk stratification tool in
patients with diabetes mellitus.
CARDIAC COMPUTED TOMOGRAPHY
The 5-year follow-up results of the Scottish Com-
puted Tomography of the Heart (SCOT-HEART) trial
were presented at this ESC congress in Munich.17
Patients with stable chest pain who were referred to a
cardiology clinic were randomized to coronary com-
puted tomography angiography (CTA) in addition to
standard care (n = 2073) versus standard care alone
(n = 2073). The initial results of this trial showed that
coronary CTA clarified the diagnosis and altered the
subsequent management of the patients at short-term
follow-up.18 Specifically, coronary CTA resulted in
cancelations of a significant number of functional tests,
increase the number of invasive coronary angiography
and led to an increase in the prescription of preventive
and antianginal medications. At 5-year follow-up, coro-
nary CTA and the associated changes in treatment
resulted in significantly lower rates of death from
coronary heart disease and nonfatal myocardial infarc-
tion compared with standard care (2.3% vs 3.9%; HR
0.59; P = 0.004). Importantly, the rates of invasive
coronary angiography and coronary revascularization
were similar at 5 years in both arms.
In the EPICardial Adipose Tissue in HEART
Diseases (EPICHEART) study,19 574 patients with
severe aortic stenosis referred to surgical aortic valve
replacement were included and the influence of epicar-
dial adipose tissue (EAT) volume on coronary artery
calcification was evaluated. Using CT, the EAT volume
was measured. In addition, quantitative proteomics of
the thoracic fat (including EAT, mediastinal, and sub-
cutaneous adipose tissue) were performed. EAT volume
was not associated with the extent of coronary artery
calcification on CT. However, quantitative proteomics
of the EAT showed that patients with coronary artery
calcification had upregulation of pro-calcifying annex-
ins, fatty acid-binding transporters, and inflammatory
signaling proteins whereas fetuin-A and antioxidant
enzymes were downregulated. In EAT, pro-calcifying
annexins regulation was positively correlated with
coronary artery calcium. This imbalance of pro-calcify-
ing, pro-inflammatory and lipid transporter mediators
was not observed in patients without coronary artery
calcification. These results indicate that the biological
characteristics of the EAT rather than the volume of
EAT exerts an influence on the coronary atherosclerotic
process. The Cardiovascular Risk Prediction using
Computed Tomography (CRISP-CT) study provided
further insight into the prognostic value of perivascular
fat characteristics.20 The signals released by the
inflamed coronary atherosclerotic plaques exert an effect
on the perivascular adipose tissue inhibiting local
adipogenesis. The changes in the composition of the
perivascular fat around the inflamed coronary arteries
result in a change in attenuation of coronary CTA (from
more negative Hounsfield unit [HU] values to less
negative) which can be quantified with the perivascular
fat attenuation index. On a derivation cohort of 1872
participants with a median follow-up of 72 months and a
validation cohort of 2040 participants with a median
follow-up of 54 months, the perivascular fat attenuation
index values around the proximal right coronary artery
and left anterior descending artery were measured on
CTA and correlated with the occurrence of all-cause and
cardiac mortality. A value of perivascular fat attenuation
index of - 70.1 HU or higher (less negative) was
associated with 2.5-fold increase in all-cause mortality
and 9-fold increase in cardiac mortality in the derivation
cohort. This cutoff value was confirmed in the validation
cohort (HR 3.69, P\ 0.001 for all-cause mortality and
HR 5.62, P\ 0.001 for cardiac mortality). Therefore,
perivascular fat attenuation index reflects coronary
inflammation and could guide preventive therapies in
primary prevention and intensify secondary prevention
in patients with CAD.
Another pioneering study describing coronary CTA
radiomics to identify novel imaging biomarkers of
plaque vulnerability was presented by Kolossvary
et al21 Coronary CTA radiomics provides multiple
quantitative metrics that describe the heterogeneity and
spatial complexity of coronary lesions, resulting in big-
data datasets, where each abnormality is characterized
by hundreds of different parameters. The investigators
aimed to assess the discriminatory power of coronary
CT radiomics to identify morphologic and/or metabolic
parameters of plaque vulnerability. A total of 44 plaques
were analyzed in 25 patients using intravascular
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ultrasound (IVUS), optical coherence tomography
(OCT), 18F-fluoride-PET, and coronary CTA. Beyond
conventional qualitative and quantitative metrics, the
investigators calculated 935 radiomic parameters of
each plaque. Morphologic vulnerability was defined by
IVUS and OCT, whereas metabolic vulnerability was
defined by 18F-fluoride-PET (Figure 4). The best con-
ventional CT metric resulted in an area under the curve
value close to random (0.52), while the best radiomic
feature had a good diagnostic accuracy (area under the
curve = 0.74) to identify morphologic plaque vulnera-
bility. Remarkably, radiomic features also outperformed
conventional CT metrics to identify metabolic plaque
vulnerability (area under the curve: 0.87 vs 0.65,
respectively). These results are promising since CT
radiomics can capture both morphologic and metabolic
high-risk plaque characteristics. Additional prospective
studies evaluating how CT radiomics may help to guide
therapy are needed.
As coronary CTA is becoming a widely available
imaging technique and one of the first-line tests used in
patients with suspected CAD, the radiation dose expo-
sure is highly relevant. Hausleiter et al. presented the
results of the Prospective Multicenter Registry on
RadiaTion Dose Estimates of Cardiac CT AngIOgraphy
iN Daily Practice (PROTECTION-VI) study that eval-
uated the radiation dose and the utilization of dose-
saving strategies for cardiac CTA.22 The study con-
ducted in 61 hospitals from 32 countries prospectively
enrolled 4502 patients undergoing cardiac CTA during
one calendar month in 2017. The coronary CTA data
were analyzed in a central core-lab and compared with a
Figure 4. Intravascular ultrasound, optical coherence tomography, 18F-sodium fluoride-PET, and
volume-rendered coronary computed tomography angiography images of three representative
coronary lesions to assess plaque vulnerability. Morphologic vulnerability was defined as the
presence of positive remodeling and posterior attenuation on intravascular ultrasound (IVUS) and
the presence of thin-cap fibroatheroma (TCFA) or intraplaque microvessels or macrophage
infiltration on optical coherence tomography (OCT). Metabolic vulnerability was defined as any
plaque showing [ 25% uptake on 18F-sodium fluoride-PET (NaF18-PET) images. Upper row
depicts a plaque showing morphologic characteristics of vulnerability. Middle row shows a lesion
with metabolic characteristics of vulnerability. Bottom row displays a plaque showing neither
morphologic nor metabolic characteristics of vulnerability. Image courtesy of M. Kolossvary. CTA,
computed tomography angiography.
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similar dose survey performed in 2007. The median
dose-length product (DLP) of coronary CTA was
195 mGy*cm, 78% lower than the DLP reported in
the 2007 survey (P\ 0.001). This reduction in radiation
dose was not associated with the increase in the number
of nondiagnostic coronary CTA (1.7% in 2007 vs 1.9%
in 2017 surveys, P = 0.55). This large international
radiation dose survey demonstrates considerable reduc-
tion of radiation exposure in coronary CTA during the
last decade and underlines the importance of training
and adaptation of contemporary cardiac scan protocols.
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